Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NATHAN L BENNETT

Allopathic & Osteopathic Physicians Family Medicine

NPI
1992775548
CMS profile
317088
Location
PITTSBURGH, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$60,463.49

168 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
AbbVie Inc. $25,619.82 79
Allergan, Inc. $13,866.22 10
Biohaven Pharmaceuticals, Inc. $11,785.61 38
Teva Pharmaceuticals USA, Inc. $5,380.49 12
Amgen Inc. $3,071.54 7
Eko Devices, Inc. $349.00 1
Novo Nordisk Inc $212.33 15
Bayer HealthCare Pharmaceuticals Inc. $71.66 1
Lundbeck LLC $35.38 1
Avanir Pharmaceuticals, Inc. $21.62 1
GlaxoSmithKline, LLC. $17.95 1
PFIZER INC. $17.54 1
E.R. Squibb & Sons, L.L.C. $14.33 1

Page 4 of 4; records 151–168 of 168 matching records. This page contains 18 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NATHAN L BENNETT

NPI 1992775548 · CMS profile ID 317088

Allopathic & Osteopathic Physicians / Family Medicine

PITTSBURGH, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–168 of 168 matching records. This page contains 18 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1992775548?year=2021&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NATHAN L BENNETT, NPI 1992775548, CMS profile ID 317088. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–168 of 168 matching records. This page contains 18 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1992775548?year=2021&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). NATHAN L BENNETT, NPI 1992775548, CMS profile ID 317088. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–168 of 168 matching records. This page contains 18 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1992775548?year=2021&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
NATHAN L BENNETT, NPI 1992775548, CMS profile ID 317088, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–168 of 168 matching records. This page contains 18 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1992775548?year=2021&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

168 matching records · $60,463.49 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 168 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–168 of 168.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Biohaven Pharmaceuticals, Inc. $11.1602/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852425155 CMS
AbbVie Inc. $9.5002/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794038219 CMS
Biohaven Pharmaceuticals, Inc. $1,500.0002/11/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852425151 CMS
AbbVie Inc. $5.5702/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794038215 CMS
Allergan, Inc. $1,440.0002/03/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792705823 CMS
AbbVie Inc. $16.6502/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794038213 CMS
Teva Pharmaceuticals USA, Inc. $2,080.0002/01/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839455531 CMS
AbbVie Inc. $2.4401/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794038209 CMS
AbbVie Inc. $4.2301/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794038205 CMS
AbbVie Inc. $2.0001/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794038201 CMS
Novo Nordisk Inc $23.3101/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811680697 CMS
AbbVie Inc. $7.0401/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794038197 CMS
Biohaven Pharmaceuticals, Inc. $9.1501/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852425147 CMS
Allergan, Inc. $1,750.0001/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792705821 CMS
Biohaven Pharmaceuticals, Inc. $8.7401/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852425143 CMS
AbbVie Inc. $8.6701/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794038193 CMS
Novo Nordisk Inc $18.3101/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810750649 CMS
AbbVie Inc. $5.3101/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794038189 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $90,952.30 212
PY2020 $101,698.70 206
PY2021 $60,463.49 168
PY2022 $84,380.25 190
PY2023 $46,708.90 186
PY2024 $46,369.65 114
PY2025 $34,428.01 91

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $124,183.55 68
PY2024 Principal investigator $34,598.29 15
PY2023 Recipient $10,808.53 7
PY2023 Principal investigator $77,309.77 32
PY2022 Principal investigator $93,922.87 72
PY2021 Principal investigator $127,787.92 81
PY2020 Recipient $150.00 1
PY2020 Principal investigator $309,566.20 73
PY2019 Recipient $5,304.20 2
PY2019 Principal investigator $341,533.48 82

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

68 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,854.00 12/31/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS
A Phase 3 Multicenter 24-Week Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Atogepant When Added to OnabotulinumtoxinA (BOTOX) for the Preventive Treatment of Chronic Migraine No dispute reported 06/30/2026 1202534049
Principal investigator 1 Ipsen Innovation $2,360.40 12/30/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians, Inc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291896
Principal investigator 1 Ipsen Innovation $3,082.80 12/30/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians, Inc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291898
Principal investigator 1 Ipsen Innovation $722.40 12/30/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians, Inc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291900
Principal investigator 1 Ipsen Innovation $722.40 12/30/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians, Inc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291906
Principal investigator 1 Ipsen Innovation $2,970.80 12/30/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians, Inc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291908
Principal investigator 1 Ipsen Innovation $722.40 12/30/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians, Inc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291910
Principal investigator 1 Ipsen Innovation $2,360.40 12/30/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians, Inc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291912
Principal investigator 1 Ipsen Innovation $2,655.80 12/30/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians, Inc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291918
Principal investigator 1 Ipsen Innovation $3,082.80 12/30/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians, Inc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291920
Principal investigator 1 Ipsen Innovation $2,970.80 12/03/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians, Inc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291892
Principal investigator 1 Ipsen Innovation $2,970.80 12/03/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians, Inc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291894
Principal investigator 1 Ipsen Innovation $722.40 12/03/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians, Inc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291902
Principal investigator 1 Ipsen Innovation $3,082.80 12/03/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians, Inc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291904
Principal investigator 1 Ipsen Innovation $722.40 12/03/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians, Inc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291914
Principal investigator 1 Ipsen Innovation $722.40 12/03/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians, Inc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291916
Principal investigator 1 Ipsen Innovation $3,082.80 10/22/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians, Inc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291886
Principal investigator 1 Ipsen Innovation $3,082.80 10/22/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians, Inc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291888
Principal investigator 1 Ipsen Innovation $3,082.80 10/22/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians, Inc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291890
Principal investigator 1 H. Lundbeck A S $2,036.00 10/15/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS RESEARCH
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251775632
Principal investigator 1 H. Lundbeck A S $1,708.00 10/15/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS RESEARCH
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251775636
Principal investigator 1 H. Lundbeck A S $1,702.00 10/15/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS RESEARCH
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251775641
Principal investigator 1 H. Lundbeck A S $2,500.00 10/10/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS RESEARCH
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251775587
Principal investigator 1 H. Lundbeck A S $600.00 10/08/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS RESEARCH
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251775447
Principal investigator 1 H. Lundbeck A S $112.00 10/08/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS RESEARCH
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251775457
Principal investigator 1 H. Lundbeck A S $103.00 10/08/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS RESEARCH
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251775461
Principal investigator 1 H. Lundbeck A S $86.00 10/08/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS RESEARCH
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251775465
Principal investigator 1 H. Lundbeck A S $216.00 10/08/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS RESEARCH
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251775468
Principal investigator 1 H. Lundbeck A S $312.00 10/08/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS RESEARCH
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251775472
Principal investigator 1 H. Lundbeck A S $125.00 10/08/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS RESEARCH
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251775476
Principal investigator 1 H. Lundbeck A S $45.00 10/08/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS RESEARCH
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251775481
Principal investigator 1 H. Lundbeck A S $2,036.00 09/10/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS RESEARCH
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251774441
Principal investigator 1 Ipsen Innovation $6,000.00 09/05/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians, Inc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291864
Principal investigator 1 Ipsen Innovation $2,500.00 09/05/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians, Inc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291866
Principal investigator 1 Ipsen Innovation $1,000.00 09/05/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians, Inc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291868
Principal investigator 1 Ipsen Innovation $2,200.00 09/05/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians, Inc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291870
Principal investigator 1 Ipsen Innovation $3,500.00 09/05/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians, Inc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291872
Principal investigator 1 Ipsen Innovation $9,000.00 09/05/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians, Inc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291874
Principal investigator 1 Ipsen Innovation $2,750.00 09/05/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians, Inc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291876
Principal investigator 1 Ipsen Innovation $2,000.00 09/05/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians, Inc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291878
Principal investigator 1 Ipsen Innovation $4,000.00 09/05/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians, Inc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291880
Principal investigator 1 Ipsen Innovation $1,500.00 09/05/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians, Inc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291882
Principal investigator 1 Ipsen Innovation $1,500.00 09/05/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians, Inc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184291884
Principal investigator 1 H. Lundbeck A S $445.00 08/07/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS RESEARCH
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251773355
Principal investigator 1 H. Lundbeck A S $2,036.00 07/09/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS RESEARCH
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251771903
Principal investigator 1 H. Lundbeck A S $1,702.00 07/09/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS RESEARCH
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251771907
Principal investigator 1 H. Lundbeck A S $2,036.00 05/07/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS RESEARCH
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251770057
Principal investigator 1 ABBVIE INC. $4,375.00 04/03/2025 Non-covered Recipient Entity
PREF PRIMARY CARE PHYSICIANS INC
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1202469614
Principal investigator 1 H. Lundbeck A S $1,500.00 04/02/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS RESEARCH
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251769390
Principal investigator 1 H. Lundbeck A S $1,200.00 04/02/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS RESEARCH
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251769403
Principal investigator 1 H. Lundbeck A S $1,000.00 04/02/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS RESEARCH
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251769407
Principal investigator 1 H. Lundbeck A S $11,608.00 04/02/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS RESEARCH
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251769412
Principal investigator 1 H. Lundbeck A S $2,000.00 04/02/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS RESEARCH
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251769416
Principal investigator 1 PFIZER INC. $1,157.75 03/20/2025 Non-covered Recipient Entity
Preferred Primary Care Physicians Research
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS No dispute reported 06/30/2026 1228723762
Principal investigator 1 ABBVIE INC. $1,447.50 03/06/2025 Non-covered Recipient Entity
PREF PRIMARY CARE PHYSICIANS INC
M22-418 - Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1202458871
Principal investigator 1 H. Lundbeck A S $72.00 03/06/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS RESEARCH
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251768488
Principal investigator 1 H. Lundbeck A S $370.36 03/05/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS RESEARCH
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251768299
Principal investigator 1 H. Lundbeck A S $238.89 03/05/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS RESEARCH
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251768303
Principal investigator 1 H. Lundbeck A S $123.64 03/05/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS RESEARCH
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251768307
Principal investigator 1 H. Lundbeck A S $26.05 03/05/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS RESEARCH
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251768311
Principal investigator 1 H. Lundbeck A S $25.00 03/05/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS RESEARCH
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251768315
Principal investigator 1 H. Lundbeck A S $126.60 03/05/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS RESEARCH
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251768319
Principal investigator 1 H. Lundbeck A S $28.00 03/05/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS RESEARCH
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251768441
Principal investigator 1 H. Lundbeck A S $36.01 03/05/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS RESEARCH
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251768445
Principal investigator 1 ABBVIE INC. $600.00 02/26/2025 Non-covered Recipient Entity
PREF PRIMARY CARE PHYSICIANS INC
M22-418 - Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1202454125
Principal investigator 1 H. Lundbeck A S $629.55 02/11/2025 Non-covered Recipient Entity
PREFERRED PRIMARY CARE PHYSICIANS RESEARCH
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251767255
Principal investigator 1 ABBVIE INC. $1,447.50 02/05/2025 Non-covered Recipient Entity
PREF PRIMARY CARE PHYSICIANS INC
M22-418 - Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1202446137
Principal investigator 1 ABBVIE INC. $1,447.50 01/02/2025 Non-covered Recipient Entity
PREF PRIMARY CARE PHYSICIANS INC
M22-418 - Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1202436102